SCHEMBL2531622

SCHEMBL2531622

Cc1c(F)cc(NC(=O)Nc2cccc(-c3nn4c(c3-c3ccncc3)SCC4)c2)c(F)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.37
BLM P54132 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
KDR P35968 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
BRAF P15056 2/20 0.34
DYRK1A Q13627 1/20 0.34
KDM4E B2RXH2 3/20 0.34
POLB P06746 2/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
PAX8 Q06710 1/20 0.34
MCL1 Q07820 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
FYN P06241 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480807 0.88 SCN5A (0.42) KDRMAPTCSNK1DCSNK1EEGFR
SCHEMBL2480345 0.81 BRAF (0.47) CNR1KDRBRAFEGFR
SCHEMBL2478428 0.81 HTT (0.48) CNR1SMN1; SMN2KMT2AMAPTGAA
SCHEMBL2476661 0.81 CNR1 (0.59) CNR1MAPT
SCHEMBL2477788 0.81 CNR1 (0.46) CNR1SMN1; SMN2PKMKMT2ABRAF
SCHEMBL2474825 0.81 SMN1; SMN2 (0.49) CNR1SMN1; SMN2KDRPKMKMT2A
SCHEMBL2480457 0.81 TAAR1 (0.43) CNR1SMN1; SMN2KMT2ALMNAALDH1A1
SCHEMBL2477515 0.80 CNR1 (0.48) CNR1BLMSMN1; SMN2KDRKMT2A
SCHEMBL2478693 0.80 CNR1 (0.48) CNR1SMN1; SMN2KDRPKMKMT2A
SCHEMBL2477777 0.80 EGFR (0.39) CNR1BLMSMN1; SMN2KDRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 CNR1 3233/4885BLM 2985/4885SMN1; SMN2 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.